< Back to all clusters
[POLITICS] · United States · 13 sources

started · updated

Medicaid drug pricing: Trump expands GENEROUS model to all 50 states

President Donald Trump has announced the expansion of the Medicaid GENEROUS drug pricing model to include all 50 states, the District of Columbia, and Puerto Rico. The initiative utilizes a 'most favored nation' approach, which aims to align the net prices of certain brand-name drugs in the U.S. with the lower prices paid in other developed nations, including the United Kingdom, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland.

The administration reports that agreements have been reached with 26 major pharmaceutical manufacturers, covering approximately 90% of the U.S. brand-name drug market. The White House estimates that these deals could save the federal and state governments billions of dollars, with one estimate suggesting a total savings of $529 billion over the next decade, while another projection cites $64.3 billion in savings specifically from the GENEROUS model.

While the administration presents this as a major victory for affordability, some health policy experts have expressed skepticism. Critics note that because the specific details of the negotiated deals are not public, the exact savings are difficult to verify. Furthermore, some experts argue that since Medicaid beneficiaries already pay very low co-payments, the primary beneficiaries of the lower prices may be state and federal budgets rather than the individual patients themselves.

Entities

Centers for Medicare & Medicaid Services · Donald Trump · Medicaid · Mehmet Oz · Robert F. Kennedy Jr. · Robert Wood Johnson Foundation · White House

Claims

What the coverage asserts, and how many sources carry each claim.